The aim of the present study was to examine the changes in intima-media thickness (IMT) and myocardial perfusion in association with other laboratory risk factors for atherosclerosis in patients treated with therapy that targeted vascular endothelial growth factor (VEGF). IMT, myocardial perfusion and laboratory risk factors of atherosclerosis were studied in 58 patients with metastatic colorectal carcinoma or metastatic renal cell carcinoma prior to and at 3-monthly intervals during anti-VEGF treatment. Compared with the pretreatment IMT, the results indicated that the IMT was consistently increased during therapy in the two patient groups. Patient blood pressure and concentration of troponin T increased transiently. An increase in the concentration of high-density lipoprotein cholesterol and decrease in the concentrations of C-reactive protein and homocysteine were also observed. Novel myocardial ischemia was evident in individual patients. In conclusion, anti-VEGF therapy affects the laboratory risk factors of atherosclerosis and results in an acceleration of atherosclerosis, as demonstrated by increased IMT.

Department of Clinical Biochemistry Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic

Department of Medicine Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic

Department of Nuclear Medicine Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic; Institute of Molecular and Translational Medicine Palacký University Medical School and Teaching Hospital Olomouc 775 20 Czech Republic

Zobrazit více v PubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. PubMed DOI

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/S0092-8674(00)81683-9. PubMed DOI

Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol. 2012;23:395–401. doi: 10.1093/annonc/mdr065. PubMed DOI

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011;378:1931–1939. doi: 10.1016/S0140-6736(11)61613-9. PubMed DOI

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al. ML18147 Study Investigators: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14:29–37. doi: 10.1016/S1470-2045(12)70477-1. PubMed DOI

Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol. 2013;14:1233–1242. doi: 10.1016/S1470-2045(13)70464-9. PubMed DOI PMC

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al. CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312. doi: 10.1016/S0140-6736(12)61900-X. PubMed DOI

Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, et al. BEVLiN Investigators: A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol. 2013;24:2396–2402. doi: 10.1093/annonc/mdt228. PubMed DOI

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al. REGARD Trial Investigators: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39. doi: 10.1016/S0140-6736(13)61719-5. PubMed DOI

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506. doi: 10.1200/JCO.2012.42.8201. PubMed DOI

Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 2007;16:439–443. doi: 10.1111/j.1365-2354.2006.00763.x. PubMed DOI

Melichar B, Králíčková P, Hyšpler R, Kalábová H, Cerman J, Jr, Holečková P, Studentová H, Malířová E. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab. Hepatogastroenterology. 2012;59:366–371. PubMed

Melichar B, Hyšpler R, Tichá A, Kalábová H, Vitásková D, Zezulová M, Dvořák J, Cerman J, Jr, Doležel M. Intestinal permeability in patients with metastatic colon cancer treated with patupilone. Clin Chem Lab Med. 2014;52:1649–1655. PubMed

Melichar B, Dvorák J, Hyspler R, Zadák Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy. 2005;51:336–338. doi: 10.1159/000088957. PubMed DOI

Melichar B, Kohout P, Brátová M, Solichová D, Králícková P, Zadák Z. Intestinal permeability in patients with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol. 2001;127:314–318. doi: 10.1007/s004320000209. PubMed DOI

Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity, Review of the literature. Anticancer Drugs. 2010;21:578–590. doi: 10.1097/CAD.0b013e3283394624. PubMed DOI

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21:1513–1523. doi: 10.1200/JCO.2003.04.173. PubMed DOI

Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–1732. PubMed

Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22:640–647. doi: 10.1200/JCO.2004.05.205. PubMed DOI

Kalábová H, Melichar B, Ungermann L, Doležal J, Krčmová L, Kašparová M, Plíšek J, Hyšpler R, Pecka M, Solichová D. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol. 2011;28:1281–1287. doi: 10.1007/s12032-010-9593-1. PubMed DOI

Melichar B, Kalábová H, Krcmová L, Kasparová M, Malírová E, Melicharová K, Pecka M, Hyspler R, Solichová D. Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. Anticancer Res. 2009;29:4813–4820. PubMed

Šrámek V, Melichar B, Indrakova J, Študentová H, Kalábová H, Vrána D, Lukešová L, Adam T, Hlídková E, Juráňová J, et al. Risk factors of atherosclerosis in patients with history of breast cancer. Pteridines. 2013;24:201–210. doi: 10.1515/pterid-2013-0033. DOI

Melichar B. Laboratory medicine and medical oncology: T he tale of two Cinderellas. Clin Chem Lab Med. 2013;51:99–112. doi: 10.1515/cclm-2012-0496. PubMed DOI

Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–7696. doi: 10.1200/JCO.2005.08.789. PubMed DOI

Melichar B, Gregor J, Solichová D, Lukes J, Tichý M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem. 1994;40:338–339. PubMed

Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V, Zadak Z. Biochemical profile and survival in nonagenarians. Clin Biochem. 2001;34:563–569. doi: 10.1016/S0009-9120(01)00261-2. PubMed DOI

Melichar B, Solichová D, Melicharová K, Malírová E, Cermanová M, Zadák Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers. 2006;21:190–198. PubMed

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity, New insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826. doi: 10.1200/JCO.2005.13.300. PubMed DOI

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212. doi: 10.1200/JCO.2007.15.6331. PubMed DOI

Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009;1:183–205. doi: 10.1177/1758834009349119. PubMed DOI PMC